Actinium Pharma Partners with Eckert & Ziegler for Ac-225 Supply Agreement

Actinium Pharmaceuticals, Inc., a pioneer in the development of targeted radiotherapies, announced it has entered into an agreement for the supply of Actinium-225 (Ac-225) with Eckert & Ziegler.

Under this agreement, Actinium Pharmaceuticals will have access to Eckert & Ziegler's high-quality Actinium-225 to further develop its lead product Actimab-A as well as additional early and late-stage development candidates for both US and international clinical trials.

Targeted radiotherapies using Ac-225 have shown great promise in the treatment of cancer. The radioisotope releases powerful alpha particles with high energy and low penetration depth, enabling precise targeting of tumour cells, including hard-to-reach micrometastases, while minimizing effects on surrounding healthy tissue. Actimab-A is an Ac-225 based radiotherapy agent, directed against CD33, a receptor overexpressed in patients with acute myeloid leukaemia (AML) and other myeloid indications.

Sandesh Seth, chairman and CEO at Actium Pharmaceuticals, Inc. commented: ""We believe that targeted radiation therapy with Actinium-225 is one of the most promising approaches for treating patients with myeloid malignancies and solid tumours. As we have highlighted recently, we are advancing our lead targeted radiotherapy Actimab-A into a pivotal phase 2/3 trial for patients with relapsed or refractory acute myeloid leukaemia and in the frontline setting in a phase 1 trial under our CRADA with the NCI. Additionally, we have launched our Actimab-A solid tumour programme to combine with PD-1 checkpoint inhibitors Keytruda and Opdivo for patients with head and neck squamous carcinoma and non-small cell lung cancer in multiple trials. As a pioneer in the development of target radiotherapies, we have aggressive plans to expand our clinical pipeline to address indications with high unmet needs. With this supply agreement with Eckert & Ziegler, we will have access to reliable and constant supply of Ac-225 to advance our product development both in the US as well as internationally.""

""We are happy to contribute to the continuous expansion of indications for Actinium-225, which is significantly being advanced by Actinium Pharmaceuticals,"" explained Dr. Harald Hasselmann, CEO of Eckert & Ziegler SE. ""The progress we have made in our Ac-225 project over the past year marks only the start of our program to address the global shortage of this vital radionuclide.""

Eckert & Ziegler reliably supplies high-quality Gallium-68, Lutetium-177, Yttrium-90, and Actinium-225 to leading pharmaceutical companies, and research institutions worldwide. With expertise in radioisotope production and global logistics, the company is committed to continuously support the development and delivery of innovative radiopharmaceuticals.

Eckert & Ziegler SE, with more than 1,000 employees, is a leading specialist in isotope-related components for nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution.

Actinium is a pioneer in the development of targeted radiotherapies intended to meaningfully improve patient outcomes.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!